Manufacturer of Controlled Substances; Notice of Application, 57570 [E6-16032]

Download as PDF 57570 Federal Register / Vol. 71, No. 189 / Friday, September 29, 2006 / Notices security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: September 20, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–16023 Filed 9–28–06; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 30, 2006, Abbott Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson Road, Whippany, New Jersey, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: Drug Schedule jlentini on PROD1PC65 with NOTICES Dihydromorphine (9145) ............... Hydromorphone (9150) ................ I II The company plans to manufacture bulk product and dosage units for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than November 28, 2006. VerDate Aug<31>2005 20:43 Sep 28, 2006 Jkt 208001 Dated: September 20, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–16032 Filed 9–28–06; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P By Notice dated June 1, 2006, and published in the Federal Register on June 8, 2006, (71 FR 33315), Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated May 17, 2006, and published in the Federal Register on May 25, 2006, (71 FR 30166), Lilly Del Caribe, Inc., Chemical Plant, Kilometer 146.7, State Road 2, Mayaguez, Puerto Rico 00680, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Dextropropoxyphene (9273), a basic class of controlled substance listed in Schedule II. The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Lilly Del Caribe, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Lilly Del Caribe, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: September 20, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–16022 Filed 9–28–06; 8:45 am] BILLING CODE 4410–09–P PO 00000 Frm 00111 Fmt 4703 Sfmt 4703 Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration Drug Codeine-N-oxide (9053) ............... Difenoxin (9168) ........................... Dihydromorphine (9145) ............... Morphine-N-oxide (9307) ............. Norlevorphanol (9634) .................. Normorphine (9313) ..................... Tetrahydrocannabinols (7370) ..... Alfentanil (9737) ........................... Amphetamine (1100) .................... Ecgonine (9180) ........................... Codeine (9050) ............................. Dextropropoxyphene, bulk (9273) Dihydrocodeine (9120) ................. Diphenoxylate (9170) ................... Diprenorphine (9058) ................... Etorphine HCL (9059) .................. Fentanyl (9801) ............................ Hydrocodone (9193) ..................... Hydromorphone (9150) ................ Levo-alphacetylmethadol (9648) .. Levorphanol (9220) ...................... Meperidine (9230) ........................ Methadone (9250) ........................ Methadone intermediate (9254) ... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Metopon (9260) ............................ Morphine (9300) ........................... Nabilone (7379) ............................ Noroxymorphone (9668) .............. Opium extracts (9610) .................. Opium fluid extract (9620) ............ Opium tincture (9630) .................. Opium, granulated (9640) ............ Opium, powdered (9639) ............. Oxycodone (9143) ........................ Oxymorphone (9652) ................... Phenazocine (9715) ..................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Thebaine (9333) ........................... Schedule I I I I I I I II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II The firm plans to manufacture the listed controlled substances for internal use and for sale to other companies. Since the publication of the Notice of Application, it has been determined that drug code 7360 (Marihuana) is not needed as a bulk manufacturing drug code for the company. The company has subsequently withdrawn their request to add this code to their current application for registration. E:\FR\FM\29SEN1.SGM 29SEN1

Agencies

[Federal Register Volume 71, Number 189 (Friday, September 29, 2006)]
[Notices]
[Page 57570]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-16032]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on May 30, 2006, Abbott 
Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson 
Road, Whippany, New Jersey, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................  I
Hydromorphone (9150).......................  II
------------------------------------------------------------------------

    The company plans to manufacture bulk product and dosage units for 
distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than November 28, 2006.

     Dated: September 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E6-16032 Filed 9-28-06; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.